Cover Image

The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD)

Abstract Background Our objective was to investigate the efficacy of the beta-3 adrenergic receptor (β3-AR) agonist BRL37344 for the prevention of liver steatosis and inflammation associated with nonalcoholic fatty liver disease (NAFLD). Methods Four groups were established: a control group (given a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ziwen Wang (Author), Shanshan Li (Author), Ruifeng Wang (Author), Liansheng Guo (Author), Dan Xu (Author), Tieyuan Zhang (Author), Yifan Xu (Author), Wenlong Wang (Author), Min Wang (Author), Zhongwei Gan (Author), Xiaobing Wang (Author)
Format:	Book
Published:	BMC, 2020-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pre-treatment of the beta3-adrenergic receptor agonist BRL37344 reduces in vivo myocardial ischemia/reperfusion injury by improving AMPK and SIRT1 activity and by suppressing mTOR and p70S6K signaling pathways
by: Dilan Askin Ozek, et al.
Published: (2023)

Green Tea and Epigallocatechin Gallate (EGCG) for the Management of Nonalcoholic Fatty Liver Diseases (NAFLD): Insights into the Role of Oxidative Stress and Antioxidant Mechanism
by: Guoyi Tang, et al.
Published: (2021)

Nonalcoholic Fatty Liver Disease (NAFLD) And Cardiovascular Risk In Renal Transplant Recipients
by: Ivana Mikolasevic, et al.
Published: (2014)

Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
by: Kalliopi Pafili, et al.
Published: (2021)

Dynamics of hepatic steatosis resolution and changes in gut microbiome with weight loss in nonalcoholic fatty liver disease
by: Jaideep Behari, et al.
Published: (2021)

Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes
by: Rohitash Jamwal, et al.
Published: (2020)

Ultrasound Score of Liver Steatosis Severity in the Diagnosis of Peripheral Arterial Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease
by: A. S. Kuznetsova, et al.
Published: (2023)

Sex hormone binding globulin (SHBG) as a predictor of liver fibrosis in subjects with nonalcoholic fatty liver disease (NAFLD)
by: Abeer Abdel-latif, et al.
Published: (2023)

Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)
by: Yuan-Ye Qiu, et al.
Published: (2023)

P- Hydroxybenzyl Alcohol Alleviates Oxidative Stress in a Nonalcoholic Fatty Liver Disease Larval Zebrafish Model and a BRL-3A Hepatocyte Via the Nrf2 Pathway
by: Jing An, et al.
Published: (2021)

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
by: Hu YB, et al.
Published: (2018)

Lycorine ameliorates liver steatosis, oxidative stress, ferroptosis and intestinal homeostasis imbalance in MASLD mice
by: Ziwen Wang, et al.
Published: (2024)

Herbal drug discovery for the treatment of nonalcoholic fatty liver disease
by: Tingting Yan, et al.
Published: (2020)

Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
by: Asieh Mansour, et al.
Published: (2024)

Chaihu Shugan powder alleviates liver inflammation and hepatic steatosis in NAFLD mice: A network pharmacology study and in vivo experimental validation
by: Sisi Lei, et al.
Published: (2022)

A review of nonalcoholic fatty liver disease - genetics and animal models
by: Ze Zheng, et al.
Published: (2016)

NUSAP1 Could be a Potential Target for Preventing NAFLD Progression to Liver Cancer
by: Taofei Zeng, et al.
Published: (2022)

Diagnostic significance of the newest biomarkers of steatosis progression in patients with stable coronary heart disease, combined with nonalcoholic fatty liver disease
by: I. I. Vakalyuk, et al.
Published: (2018)

The association between endocrine disrupting chemicals and nonalcoholic fatty liver disease: A systematic review and meta-analysis
by: Kai Pan, et al.
Published: (2024)

Metagenome of Gut Microbiota of Children With Nonalcoholic Fatty Liver Disease
by: Yuzhen Zhao, et al.
Published: (2019)

Nonalcoholic Fatty Liver Disease An Update
Published: (2019)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023)

Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease
by: Gwyneth Shook Ting Soon, et al.
Published: (2021)

Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease
by: Xue-Kai Wang, et al.
Published: (2021)

Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease
by: Caihua Wang, et al.
Published: (2019)

Patophysiology of nonalcoholic fatty liver disease
by: Ewa Krzewicka-Romaniuk, et al.
Published: (2019)

Patophysiology of nonalcoholic fatty liver disease
by: Ewa Krzewicka-Romaniuk, et al.
Published: (2019)

Nonalcoholic Fatty Liver Disease and Ayurveda
by: Sanjeev Sharma, et al.
Published: (2023)

The NAFLD fibrosis score : a prognostic predictor for mortality and liver complications among NAFLD patients
by: Sombat Treeprasertsuk
Published: (2013)

Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development
by: Lu Wang, et al.
Published: (2023)

α‐Tocopherol suppresses hepatic steatosis by increasing CPT‐1 expression in a mouse model of diet‐induced nonalcoholic fatty liver disease
by: Masanori Tokoro, et al.
Published: (2021)

Association of Dietary Acid Load with Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in US Adults: Evidence from NHANES 1999–2018
by: Cheng J, et al.
Published: (2023)

Astragaloside IV Improves High-Fat Diet-Induced Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Rats by Regulating Inflammatory Factors Level via TLR4/NF-κB Signaling Pathway
by: Ying-Li Liu, et al.
Published: (2021)

Arsenic exposure and risk of nonalcoholic fatty liver disease (NAFLD) among U.S. adolescents and adults: an association modified by race/ethnicity, NHANES 2005-2014
by: Jennifer K. Frediani, et al.
Published: (2018)

Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats
by: Long Li, et al.
Published: (2015)

Stress kinases in the development of liver steatosis and hepatocellular carcinoma
by: Beatriz Cicuéndez, et al.
Published: (2021)

Risk Factors for Liver Steatosis in Obese Children and Adolescents
by: Yu-Cheng Lin, et al.
Published: (2010)

Therapeutic roles of a natural herbal product on ameliorating hepatic steatosis via gut dysbacteriosis modulating in treatment of nonalcoholic fatty liver disease in mice
by: Xiaoan Ren, et al.
Published: (2021)

A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis
by: Maddalena Parafati, et al.
Published: (2018)

The relationship between folic acid and nonalcoholic fatty liver disease
by: Bing'er Xu, et al.
Published: (2024)